The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|42|10|1192-1199

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.10, 2015-11, pp. : 1192-1199

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 10, 2015-11 ,pp. : 1192-1199

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab in severe ulcerative colitis – is it useful for all patients?

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1413-1413

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab in severe ulcerative colitis – is it useful for all patients? Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1413-1414

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ulcerative colitis endoscopic index of severity is associated with long‐term prognosis in ulcerative colitis patients treated with infliximab

By  

DIGESTIVE ENDOSCOPY, Vol. 28, Iss. 6, 2016-09 ,pp. : 665-670

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pericarditis during infliximab therapy in paediatric ulcerative colitis

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 43, Iss. 1, 2018-02 ,pp. : 107-109

John Wiley & Sons Inc

Access to resources Recommend Favorite